According to previous reports by GPCR3D, Retatrutide (LY3437943) is a triple agonist peptide developed by Eli Lilly that targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R)
Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD et al
Its also great for anyone who has trouble swallowing pills
Your nutrition coach personalizes the protocol framework to accommodate dietary restrictions, cultural food preferences, budget considerations, and time constraints that might otherwise create adherence challenges
This dual-action approach not only helps with weight management but directly impacts sleep apnea severity